Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Complex carbohydrates
- Glycocalyx: the cell surface carbohydrate layer
- Cell surface carbohydrate interactions
- Biosynthesis of oligosaccharides
- Many tumor markers are Carbohydrates
- Pathogens infecting by carbohydrate recognition
- Lectins: native carbohydrate-binding proteins
- The selectins are therapeutic targets
- Enhancing carbohydrate-lectin interaction
- Bioactive conformation of glycomimetic 69669a
- Preorganization of the bioactive conformation
- Enhancing binding affinity for E-selectin
- E & P-selectins binding to native ligand PSGL-1
- Glycosylation and sulfation of PSGL-1
- Sulfated drug-like fragment-based library
- GMI-1070 is a pan selectin antagonist
- GMI-1070: pre-clinical models
- Effect of GMI-1070 animal models
- Sickle cell Vaso-Occlusive Crisis (VOC)
- Testing the effects of GMI-1070 on VOC
- GMI-1070 for vaso-occlusive crisis
- Effects of GMI-1070 in sickle cell mice
- GMI-1070 extends survival in sickle cell mice
- GMI-1070- synthesized through convergent steps
- Scale-up chemistry and process development
- Organizations involved in GMI-1070 synthesis
- GMI-1070: phase I clinical trial
- Pharmacokinetics of a single dose of GMI-1070
- Phase 1 healthy volunteers - safety summary
- Clinical trials testing effects of GMI-1070
- GMI-1070: summary
- Validation of the potential of glycomimetic drugs
- Summary
- Scientific contributors
Topics Covered
- Glycobiology as an untapped source of innovative drugs
- Rationally designed selectin antagonists based on functional carbohydrates
- Application to inflammation in sickle cell disease crisis
- Drug-like properties now in Phase II clinical trials
- Recognition and validation of glycomimetic drugs by the pharmaceutical industry
Talk Citation
Magnani, J. (2012, November 27). Glycobiology: an untapped source of novel drugs [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/TTKR2837.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. John Magnani has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.